biostudies-literaturePeta KTSAMRC Extramural Unit for Stem Cell Research and TherapySouth African Medical Research Council Self-Initiated Research GrantSouth African Medical Research Council University Flagship Project (SAMRC-RFA-UFSP-01-2013/STEM CELLS)National Research Foundation Competitive Support for Unrated Researchers898-911https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947225biostudies-literatureUnknown41(7)The prevalence of breast cancer (BC) continues to increase and is the leading cause of cancer deaths in many countries. Numerous in vitro and in vivo studies have demonstrated that 2-methoxyestradiol (2-ME) has antiproliferative and antiangiogenic effects in BC, thereby inhibiting tumour growth and metastasis. We compared the effect of 2-ME in early- and late-stage BC using a transgenic mouse model-FVB/N-Tg(MMTV-PyVT)-of spontaneously development of aggressive mammary carcinoma with lung metastasis. Mice received 100 mg/kg 2-ME treatment immediately when palpable mammary tumours were identified (early-stage BC; Experimental group 1) and 28 days after palpable mammary tumours were detected (late-stage BC; Experimental group 2). 2-ME was administered via oral gavage three times a week for 28Cell biochemistry and functionEffect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model.PMC10947225114044A1A982Ambele MADurandt CPepper MSvan Heerden MBPeta KTJoubert AMfalseEffect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model.The prevalence of breast cancer (BC) continues to increase and is the leading cause of cancer deaths in many countries. Numerous in vitro and in vivo studies have demonstrated that 2-methoxyestradiol (2-ME) has antiproliferative and antiangiogenic effects in BC, thereby inhibiting tumour growth and metastasis. We compared the effect of 2-ME in early- and late-stage BC using a transgenic mouse model-FVB/N-Tg(MMTV-PyVT)-of spontaneously development of aggressive mammary carcinoma with lung metastasis. Mice received 100 mg/kg 2-ME treatment immediately when palpable mammary tumours were identified (early-stage BC; Experimental group 1) and 28 days after palpable mammary tumours were detected (late-stage BC; Experimental group 2). 2-ME was administered via oral gavage three times a week for 282023-01-01T00:00:00Z2023 Oct2025-05-29T22:17:12.896Z2025-05-29T22:17:12.896ZS-EPMC109472253764915810.1002/cbf.3842